Lesson
Model IBS as a Disorder of Gut-Brain Interaction
IBS is a real disorder of gut-brain interaction. Symptoms can arise from several interacting mechanisms even when routine structural testing is normal.
- Visceral hypersensitivity
- Motility
- Epithelial and immune signaling
- Microbiota
- Central processing
Distention and motility can generate amplified afferent signals.
Motor, secretory, immune, and microbial inputs shape the bowel pattern.
Attention, threat, sleep, mood, and experience can modify the final symptom.
Replace the false structural-versus-psychological divide
IBS is defined by recurrent abdominal pain linked to altered bowel habits. Neural, motor, secretory, immune, microbial, and cognitive-affective systems can amplify one another. Normal endoscopy does not make the symptoms imaginary, and stress can modify symptoms without being their sole cause.
Connect sensation to pain
Visceral afferent signaling and central processing can lower the threshold at which normal distention or motility is experienced as pain. Prior infection, inflammation, sleep disruption, trauma, anxiety, and learned threat responses can influence this network, but no single history is required for diagnosis.
Connect transit to stool form
Accelerated colonic transit tends to favor urgency and loose stool, while slower transit favors hard stool and straining. Secretion, bile acids, diet, medication exposure, and pelvic floor function can modify the same phenotype.
Use mechanisms to guide, not overpromise
A mechanism-informed plan may target stool form, pain processing, diet-triggered fermentation, or behavioral amplification. Treatment remains iterative because the dominant mechanism may differ between patients and can change over time.
Quick check
Lesson
Make a Positive Diagnosis and Triage Alarm Features
A careful history, physical examination, limited targeted testing, and absence of alarm features usually support a positive diagnosis without exhaustive exclusionary testing.
- Rome IV
- Alarm features
- Celiac serology
- Fecal calprotectin
- Medication review
Recurrent pain connects to defecation or changed stool frequency or form.
Bleeding, anemia, weight loss, fever, nocturnal symptoms, and progression reopen the pathway.
Use celiac serology and inflammatory screening in diarrhea phenotypes when appropriate.
Apply the symptom criteria
Rome IV defines IBS by recurrent abdominal pain, on average at least one day per week in the last three months, associated with defecation and/or a change in stool frequency or form. Criteria should be fulfilled for the last three months with symptom onset at least six months before diagnosis.
Look for a different disease when the pattern demands it
Gastrointestinal bleeding, unexplained iron-deficiency anemia, unintentional weight loss, nocturnal symptoms, fever, a palpable mass, progressive or severe new symptoms, and a relevant family history can justify broader evaluation. New onset later in life and an abrupt change from a stable pattern also deserve context-specific assessment.
Use targeted tests rather than a universal panel
ACG guidance supports celiac serology in patients with diarrhea symptoms. In suspected IBS-D without alarm features, fecal calprotectin and C-reactive protein can help exclude inflammatory bowel disease. Stool pathogen testing, colonoscopy, thyroid testing, bile acid evaluation, or other studies should follow the presentation rather than a reflex order set.
Audit medicines and substances
Metformin, magnesium, laxatives, antibiotics, colchicine, prostaglandins, sugar alcohols, caffeine, alcohol, opioids, anticholinergics, iron, calcium, and many other exposures can create or amplify bowel symptoms. A medication timeline can be more informative than another nondirected test.
Quick check
Lesson
Classify the Bowel Pattern Before Choosing Therapy
IBS subtype is determined from stool form on abnormal bowel-movement days, not from one memorable episode or the patient's last stool.
- Bristol Stool Form Scale
- IBS-C
- IBS-D
- IBS-M
- IBS-U
More than 25 percent with less than 25 percent loose supports IBS-C.
More than 25 percent hard and more than 25 percent loose supports IBS-M.
More than 25 percent with less than 25 percent hard supports IBS-D.
Define the stool-form anchors
Bristol types 1 and 2 are hard or lumpy stools. Types 6 and 7 are loose or watery stools. Types 3 through 5 are neither subtype-defining extreme. Classification uses the proportion of abnormal bowel movements with hard or loose forms.
Assign the subtype
IBS-C has more than 25 percent hard stools and less than 25 percent loose stools. IBS-D has more than 25 percent loose stools and less than 25 percent hard stools. IBS-M has more than 25 percent of both. IBS-U meets IBS criteria but does not fit the other stool-pattern thresholds.
Separate bowel habit from pain
Constipation or diarrhea without recurrent abdominal pain can represent functional constipation, chronic idiopathic constipation, functional diarrhea, medication effects, or another condition. The pain-bowel relationship is central to IBS classification.
Expect phenotype movement
A patient may move between subtypes. Reclassify when the sustained pattern changes and avoid continuing a constipation-directed or diarrhea-directed drug solely because it was once appropriate.
Quick check
Lesson
Build the Foundation Before Escalating Medication
A credible explanation, shared goals, regular routines, soluble fiber, and a structured dietary trial can improve outcomes and make later drug response interpretable.
- Therapeutic relationship
- Soluble fiber
- Low-FODMAP trial
- Reintroduction
- Sleep and activity
Select pain, urgency, stool form, bloating, or function as the first target.
Titrate soluble fiber or use a limited diet trial with a decision date.
Liberalize food, preserve routines, and avoid permanent unnecessary restriction.
Set a specific treatment target
Ask which domain most limits life: pain, urgency, stool frequency, incomplete evacuation, bloating, food fear, or unpredictability. Track that outcome alongside function and adverse effects instead of asking only whether IBS is better.
Use soluble rather than abrasive fiber
Psyllium can improve global symptoms and stool consistency. Start low and titrate with adequate fluid because rapid escalation can worsen gas or bloating. Coarse insoluble bran can aggravate symptoms and is not interchangeable with soluble fiber.
Run a limited low-FODMAP experiment
A limited trial can reduce global symptoms in selected patients. The sequence is short restriction, structured reintroduction, and personalization. Dietitian guidance is preferred when available, especially with nutritional risk, eating-disorder history, multiple restrictions, or complex comorbidity.
Protect nutrition and normal life
Regular meals, hydration, movement, sleep, and individualized trigger reduction may help. Avoid indefinite broad food exclusion, unsupported allergy panels, and language that turns every symptom into evidence of dietary failure.
Quick check
Lesson
Treat Pain and Bloating Across Subtypes
Pain may require a gut-directed therapy even after stool form improves. Select the intervention from mechanism, comorbidity, safety, and the guideline's level of certainty.
- Peppermint oil
- Antispasmodics
- Tricyclic antidepressants
- Gut-directed psychotherapy
- SSRIs
Use a defined cramping trial while respecting reflux and anticholinergic risk.
Reduce pain processing while accounting for transit and cardiac safety.
Change gut-brain amplification without dismissing the biology of pain.
Use peppermint oil with context
Enteric-coated peppermint oil can improve global symptoms and pain in some adults. Reflux, dyspepsia, product variability, and formulation matter. It is a symptom treatment, not a cure or a substitute for evaluating alarm features.
Explain the antispasmodic disagreement
AGA guidance conditionally supports antispasmodics, while ACG recommends against the antispasmodics currently available in the United States for global IBS symptoms because evidence is limited. A short, individualized trial for cramping may still occur, but the goal and stop rule should be explicit.
Use dicyclomine safely when selected
The current label starts oral dicyclomine at 20 mg four times daily and permits an increase after one week, but requires discontinuation if efficacy is absent within two weeks or lower doses are not tolerated. Anticholinergic effects and contraindications such as glaucoma, obstruction, severe ulcerative colitis, myasthenia gravis, reflux esophagitis, and nursing require review.
Use gut-brain therapy and neuromodulation deliberately
Gut-directed cognitive behavioral therapy and hypnotherapy can improve global symptoms. Low-dose tricyclic antidepressants can reduce pain and may slow transit, which can favor IBS-D but worsen constipation. Both AGA subtype guidelines conditionally recommend against SSRIs for IBS symptom control, though an SSRI may still be indicated for a separate psychiatric condition.
Quick check
Lesson
Treat IBS-C by the Outcome That Still Needs Work
Constipation treatment should distinguish stool-frequency relief from global IBS relief, including abdominal pain and bloating.
- Psyllium
- Polyethylene glycol
- Stimulant laxatives
- Global symptoms
- Escalation
Improve stool consistency and global symptoms through slow titration.
Increase bowel movements while measuring abdominal pain separately.
Recognize outlet dysfunction when soft stool still cannot be passed normally.
Start with the right fiber
A low, slowly titrated psyllium dose can improve stool form and global symptoms. Adequate fluid matters, while obstruction risk, swallowing difficulty, impaction, and severe fluid restriction require caution.
Use polyethylene glycol for the stool target
Polyethylene glycol can improve bowel frequency and consistency. ACG suggests against using it to treat global IBS-C symptoms because pain and bloating benefit is not established, while AGA conditionally supports it. This is a difference in outcome framing, not a contradiction about laxation.
Use stimulant laxatives as rescue or a defined trial
Bisacodyl or senna can be useful for constipation, but cramping and urgency may limit them. They do not have strong evidence for global IBS symptom relief. Long-term use should be individualized rather than reflexively described as addictive or forbidden.
Escalate when the unmet outcome is clear
Persistent pain, bloating, and constipation despite a sound foundation can justify an IBS-C prescription drug. Pelvic floor symptoms, digital maneuvers, marked straining, or refractory evacuation difficulty can require anorectal testing and biofeedback rather than more secretion.
Quick check
Lesson
Select IBS-C Prescription Therapy
Secretagogues and tenapanor improve constipation and can improve abdominal symptoms, but their labels differ by age, sex, dosing, administration, and dehydration risk.
- Linaclotide
- Plecanatide
- Lubiprostone
- Tenapanor
- Diarrhea safety
Increase chloride and bicarbonate secretion through CFTR.
Activate intestinal chloride transport within its adult-women IBS-C indication.
Reduce sodium absorption and take immediately before the first meal and dinner.
Differentiate the guanylate cyclase C agonists
Linaclotide and plecanatide activate guanylate cyclase C, increasing intestinal chloride and bicarbonate secretion through CFTR. Linaclotide is 290 mcg once daily for adult IBS-C, and 145 mcg once daily for IBS-C age 7 and older, taken on an empty stomach at least 30 minutes before a meal. Plecanatide is 3 mg once daily for adult IBS-C with or without food.
Apply the current pediatric warnings
Linaclotide is contraindicated in patients younger than 2 years and now has labeled IBS-C use from age 7. Plecanatide is contraindicated below age 6 and should be avoided from age 6 through 17 because safety and effectiveness are not established. Both require suspension and rehydration if severe diarrhea occurs.
Use lubiprostone within its indication
Lubiprostone activates intestinal chloride transport and is labeled for IBS-C in women age 18 and older at 8 mcg twice daily with food and water. Swallow capsules whole. Nausea, diarrhea, syncope or hypotension, and transient dyspnea require counseling; mechanical obstruction is a contraindication.
Use tenapanor as an NHE3 inhibitor
Tenapanor reduces intestinal sodium absorption and increases luminal water. The adult IBS-C dose is 50 mg twice daily immediately before breakfast or the first meal and immediately before dinner. It is contraindicated below age 6 and in mechanical obstruction, should be avoided from age 6 through 11, and is not established below age 18.
Quick check
Lesson
Control IBS-D Symptoms Without Missing the Cause
Urgency and loose stools can improve with symptom treatment, but fever, blood, nocturnal diarrhea, dehydration, recent antibiotics, travel, and medication exposure can signal a different pathway.
- Hydration
- Loperamide
- Bismuth
- Bile acid diarrhea
- Infection red flags
New red flags require evaluation before antimotility treatment.
Target frequency and urgency without promising reliable global pain relief.
Look beyond IBS when the exposure, anatomy, or pattern changes probability.
Triage a new diarrhea pattern
Acute or newly changed diarrhea with blood, fever, severe pain, toxicity, dehydration, recent antibiotics, outbreak exposure, or immunocompromise should not be automatically labeled IBS. Restore fluid and electrolytes and investigate the likely cause.
Use loperamide for the stool target
Loperamide can reduce stool frequency and urgency, but evidence for global IBS symptoms and pain is weak. Avoid it in bloody diarrhea, high fever, suspected invasive infection, acute severe ulcerative colitis, or ileus. Excess dosing can cause serious ventricular arrhythmia and death.
Keep bismuth in its proper role
Bismuth subsalicylate can help short-term nonspecific diarrhea, but salicylate exposure, anticoagulants, bleeding risk, kidney impairment, viral illness in children or adolescents, and benign tongue or stool darkening require context. It is not a core long-term global IBS treatment.
Consider treatable mimics
Bile acid diarrhea can resemble IBS-D, especially with marked urgency or after ileal disease or resection. Lactose intolerance, celiac disease, microscopic colitis, infection, medication effects, and inflammatory bowel disease also require selective consideration.
Quick check
Lesson
Select IBS-D Prescription Therapy
Rifaximin, eluxadoline, and alosetron serve different patients. Regimen duration, anatomy, alcohol exposure, hepatic function, constipation risk, and prior response determine selection.
- Rifaximin
- Eluxadoline
- Alosetron
- Retreatment
- Pancreatitis and ischemic colitis
Use 550 mg three times daily for 14 days with up to two retreatments.
Exclude patients without a gallbladder and screen pancreatitis risk before use.
Limit use to severe refractory IBS-D in women with strict constipation and ischemia stop rules.
Use rifaximin as a defined course
Rifaximin is labeled for adult IBS-D at 550 mg three times daily for 14 days, with or without food. Recurrence can be retreated up to two times with the same regimen. Review rifamycin hypersensitivity, severe hepatic impairment, P-glycoprotein inhibitors, and the possibility of Clostridioides difficile-associated diarrhea.
Screen eluxadoline before prescribing
Eluxadoline is typically 100 mg twice daily with food, or 75 mg twice daily for selected patients. It is contraindicated without a gallbladder, with biliary obstruction or sphincter of Oddi dysfunction, more than three alcoholic drinks daily or alcohol-use disorder, prior pancreatitis or pancreatic structural disease, severe hepatic impairment, severe chronic constipation, or mechanical obstruction.
Teach the pancreatitis stop rule
Acute epigastric or right-upper-quadrant pain that may radiate to the back or shoulder, with or without nausea and vomiting, requires immediate discontinuation and medical evaluation. Serious pancreatitis and sphincter of Oddi spasm can occur early, especially in patients without a gallbladder.
Reserve alosetron for its narrow population
Alosetron is indicated only for women with severe chronic IBS-D who have not responded adequately to conventional therapy. Start 0.5 mg twice daily, consider 1 mg twice daily after four weeks if needed and tolerated, and stop immediately for constipation or symptoms of ischemic colitis. Fluvoxamine and multiple gastrointestinal or vascular conditions are contraindications.
Quick check
Lesson
Measure Response, Reassess the Pattern, and Protect Safety
IBS care is a sequence of defined trials. Continue what improves the target without unacceptable burden, stop what fails, and reopen the diagnosis when the clinical pattern changes.
- Response domains
- Stop rules
- Subtype change
- Pregnancy and lactation
- Shared decisions
Track pain, stool form, urgency, bloating, daily activity, and adverse effects.
Use a preplanned review date instead of accumulating indefinite therapy.
New alarm features or a sustained subtype shift require a fresh clinical model.
Measure several domains
Track abdominal pain, stool frequency and form, urgency, straining, incomplete evacuation, bloating, sleep, food restriction, and daily function. A drug can succeed in one domain and fail globally, so the decision should reflect the patient's priority.
Use explicit stop and escalation rules
Stop severe diarrhea-producing secretagogues and rehydrate. Stop eluxadoline for pancreatitis or sphincter symptoms. Stop alosetron for constipation or ischemic-colitis symptoms. Reassess anticholinergics when cognition, urinary retention, glaucoma, tachycardia, or constipation emerges.
Reopen the differential when the story changes
New bleeding, anemia, fever, weight loss, nocturnal symptoms, progressive pain, persistent vomiting, abnormal inflammatory markers, or a major subtype shift may require renewed evaluation rather than another empiric IBS medication.
Use current pregnancy and lactation sections
Do not use obsolete pregnancy letters. Review the current label, systemic exposure, animal and human data, lactation information, disease burden, and alternatives for each product. Several IBS drugs have limited human pregnancy or milk data, so a class-wide statement is unsafe.
Preserve patient agency
Discuss cost, access, dosing burden, food timing, adverse effects, and the patient's tolerance for uncertainty. A high-quality plan can combine diet, a stool-directed drug, pain treatment, and gut-directed behavioral therapy without implying that every patient needs every layer.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 124 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- ACG clinical guideline for management of irritable bowel syndrome
- AGA guideline for pharmacological management of IBS-C
- AGA guideline for pharmacological management of IBS-D
- DailyMed Linzess prescribing information
- DailyMed Trulance prescribing information
- DailyMed Amitiza prescribing information
- DailyMed Ibsrela prescribing information
- DailyMed Xifaxan prescribing information
- DailyMed Viberzi prescribing information
- DailyMed Lotronex prescribing information
- DailyMed dicyclomine prescribing information